Immuron Q3 Sales reach 150% of 1H Sales
April 06 2023 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to announce the Q3
FY23 sales* results of its over-the-counter gastrointestinal and
digestive health immune supplement Travelan® and Protectyn®.
Global Q3 YTD sales of Travelan® and Protectyn®
increased by 239% in FY23 to AUD $1.46 M, compared to AUD $430 k
for the corresponding period in FY22.
In Australia, Travelan® and Protectyn® sales for
Q3 were AUD $577 k, a 101% increase on sales for 1H FY23 (AUD
$287 k). Australian Travelan® and Protectyn® Q3 YTD FY23 sales
were AUD $864 k representing a significant increase over the
corresponding period in FY22 (AUD $80k). Travelan® sales increase
as overseas travel rebounds. Australian resident short term
departures in January 2023 were 80% of those in January 2019
(Australian Bureau of Statistics). Immuron continues to restock
wholesalers in line with increasing pharmacy sales.
North American Travelan® Q3 FY23 sales were AUD
$298 k, greater than sales for 1H FY23 (AUD $297 k). North
American Travelan® Q3 YTD FY23 sales were AUD $595 k, up by 70% on
the corresponding period in FY22 (AUD $350 k). This growth was
attributable to increasing sales in both Passport Health Travel
Clinics and distributor sales. While not at pre-pandemic peak,
sales in the US are anticipated to increase as Immuron replenishes
and builds inventory.
Immuron is focused on growing sales of its
commercial products, expanding its portfolio of products and has a
strong existing pipeline.
*Unaudited
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
About Travelan®
Travelan® is an orally administered passive
immunotherapy that prophylactically reduces the likelihood of
contracting travelers’ diarrhea, a digestive tract disorder that is
commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletized preparation of hyper
immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers’ diarrhea. In
Australia, Travelan® is a listed medicine on the Australian
Register for Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024